Novo Nordisk Q3 2024 outcomes

Novo Nordisk on Wednesday reported third quarter earnings broadly according to expectations and narrowed its 2024 full-year development steerage.

The Danish pharmaceutical large mentioned that its internet revenue within the third quarter hit 27.3 billion Danish kroner ($3.92 billion), above an LSEG combination estimate of 26.95 billion Danish kroner.

EBIT — earnings earlier than tax and revenue — got here to 33.8 billion Danish kroner, additionally simply above the LSEG forecast of 33.51 billion Danish kroner.

The corporate additionally narrowed its gross sales development steerage for the total 12 months 2024 to 23% to 27% from 22% to twenty-eight% at fixed alternate charges.

Novo Nordisk has weathered more and more robust competitors, but in addition obtained promising information within the weight-loss house in current months.

Final week, the U.S. Meals and Drug Administration mentioned all doses of Wegovy have been now out there within the U.S. after beforehand noting that the bottom dose of Wegovy was briefly provide. The information was taken as a sign that Novo Nordisk’s efforts to ramp up provides of Wegovy and diabetes drug Ozempic are paying off.

Additionally in October, a research confirmed that Ozempic may cut back the danger of growing Alzheimer’s illness, suggesting its potential to delay or stop the memory-robbing situation.

— CNBC’s Annika Kim Constantino contributed to this story